The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The QuANTUM-First trial: What is the impact of MRD on the management of patients with FLT3-mutated AML?
Featured:
Alexander PerlDuring the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak with Alexander Perl, University of Pennsylvania, Philadelphia, US. We asked, The QuANTUM-First trial: What is the impact of MRD on the management of patients with FLT3-mutated acute myeloid leukemia?
The QuANTUM-First trial: What is the impact of MRD on the management of patients with FLT3-mutated AML?
Perl discusses the phase III QuANTUM-First trial (NCT02668653) evaluating the impact of FLT3-internal tandem duplication (ITD) measurable residual disease (MRD) positivity as measured by a highly sensitive polymerase chain reaction-next-generation sequencing assay on long-term survival outcomes, and how quizartinib affects MRD levels vs placebo. He then highlights data from the phase III MORHO trial (NCT02997202) assessing the impact of FLT3-ITD MRD status before allogeneic hematopoietic stem cell transplant on posttransplant survival outcomes. Perl concludes by considering the potential integration of FLT3-ITD MRD measurement into routine clinical practice for risk stratification and to guide treatment options.
